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Chronic murine leukemia viruses (MuLVs) are retroviruses which induce leukemias/lymphomas after long latency
periods. The induction of leukemia by MuLVs is complex, requiring multiple steps beginning with infection of an
appropriate target cell. A number of investigators have proposed a bone marrow – thymus axis in the development of
retrovirus induced T-cell lymphoma in which cells are initially infected in the bone marrow. These bone marrow cells
or their progeny migrate to the thymus during the disease process. In our system using adult, immunocompetent
BALB.K mice infected with E-55(/) MuLV, a similar pattern is seen; integrated virus is initially detectable in the bone
marrow and spleen and only later in the thymus. In order to better understand the leukemic process, we analyzed the
bone marrow from adult, immunocompetent BALB.K mice infected with the E-55(/) MuLV in bone marrow colony
assays. The results from these assays demonstrate that either a pluripotent progenitor cell or an early progenitor cell
is a target in the bone marrow for the virus. q 1996 Academic Press, Inc.
A bone marrow–thymus axis in the development of T-cell leukemia, implying that a bone marrow cell is in-
fected initially but that in order for a T-cell leukemia toMuLV-induced T-cell lymphoma has been proposed by
several investigators to describe the trafficking pattern develop a thymus is necessary (6). In adult, immunocom-
petent BALB.K mice infected with E-55(/) MuLV, prelimi-of virus-infected cells in vivo from initial infection to the
development of leukemia (1–5). In AKR mice, endoge- nary evidence also suggests a similar bone marrow–
thymus axis in T-cell lymphomagenesis (4).nous MuLV infectious cell centers (ICCs) can be detected
initially in the bone marrow and then subsequently in the The target cell population for MuLVs in the bone
marrow as well as the cell population, if any, whichspleen and thymus (7 to 8 days after birth), suggesting
that the cells infected in the bone marrow migrate from migrates from the bone marrow to the thymus remains
unknown. Studies using Friend polycythemia virus, anthe bone marrow to the spleen and ultimately to the
thymus (1, 5). Additionally, studies in AKR mice have acute transforming retrovirus, whose env gene en-
demonstrated that inoculation of irradiated (AKR 1 DBA/ codes for a glycoprotein that mimics erythropoietin by
2)F1 mice with AKR bone marrow cells results in leuke- binding to the erythropoietin receptor, have demon-
mia with a shorter latency period than when splenocytes strated a mature burst-forming unit of the erythroid lin-
or thymocytes are used, implying that the endogenous eage (BFU-E) as the target cell associated with Friend
virus appears earliest in the bone marrow (2). Studies virus induced erythroleukemia (7, 8). The earliest cell
using radiation leukemia virus (RadLV) have demon- associated with disease induced by RadLV has been
strated ICCs in the bone marrow early in the infection demonstrated to be a bone marrow cell, possibly a
and only later in the spleen and thymus (3). In Gross prothymocyte (3). Similar studies with Moloney MuLV
virus infection, which usually induces a T-cell leukemia, infection also indicate that preleukemic cells are first
removal of the thymus prior to injection of virus prevents detectable in the bone marrow and spleen (9). Subse-
disease development, suggesting a role for the thymus quent studies demonstrated that tumorigenesis was re-
or thymic environment in the development of leukemia lated to proliferation of null cells (10) and increased
(6). In addition, investigators demonstrated that removal hematopoiesis of cells of the myeloid lineage (11).
of the thymus 1 month after Gross virus injection results We have demonstrated previously that in E-55(/) in-
in the development of a myeloid leukemia instead of a fection of adult immunocompetent BALB.K mice, the bone
marrow and spleen express high levels of integrated
provirus early after infection (1 week after virus injection)1 To whom correspondence and reprint requests should be ad-
(4). In order to identify a possible target population fordressed at Department of Pathology, Montefiore Medical Center, Cen-
tral 302, 111 East 210th Street, Bronx, NY 10467. Fax: (718) 882-8461. the E-55(/) MuLV in the bone marrow, a series of bone
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TABLE 1
Results from the Bone Marrow Colony Assays
No growth factor GM-CSF IL-3 EPO IL-3 / EPO
Normal bone marrow 0% 0% 0% 0% 0%
T  0 T  51 T  44 T  18 T  17
n  5 n  6 n  5 n  2 n  2
a  0 { 0 a  146 { 76 a  16 { 10 a  10 { 4 a  41 { 21
Infected bone marrow 0% 40% 32% 30% 20%
T  0 T  108 T  74 T  20 T  25
n  8 n  11 n  8 n  3 n  3
a  0 { 1 a  205 { 80 a  23 { 16 a  7 { 4 a  35 { 12
Note. The percentage of colonies positive for integrated virus by PCR is indicated. T, total number of colonies analyzed by PCR; n, number of
mice examined; a, average number of colonies per 5 1 104 cells { standard deviation after 7 days.
marrow colony assays was performed using a modified onies were detected with all growth factors including
those which resulted in the generation of nonlymphoidmethod of Stanley et al. (12, 13). The assays involved
culturing 7.5 1 104 bone marrow cells either from adult cells, the results from the bone marrow assays imply
that the target cell population for the E-55(/) MuLV isBALB.K mice 1 week after E-55(/) MuLV injection or
from normal uninfected BALB.K mice in the presence or an uncommitted, pluripotent progenitor cell capable of
differentiation into any hematopoietic lineage or earlyabsence of the growth factors GM-CSF (10 ng/ml), IL-3
(1:1000), erythropoietin (EPO) (2 units/ml), or IL-3 plus progenitor cells from multiple hematopoietic lineages.
The development of leukemia is a complex processEPO. After 7 days in culture, the total number of colonies
in each plate was counted and 10 individual colonies requiring multiple steps beginning with the infection of
an appropriate target cell. Although investigators usingfrom each condition were subjected to PCR analysis.
Genomic DNA from each colony was amplified by PCR chronic MuLVs other than E-55(/) MuLV have shown
that the bone marrow is the initial site of infection, thewith two sets of primers (4). The first set of primers was
specific for the env gene of E-55(/) virus while the sec- target cell in the bone marrow has not been well defined
(1–3, 5, 7, 9–11, 15–17). Investigators have demon-ond set of primers was specific for the murine b actin
gene. The actin primers were used as an internal control strated that the target cell associated with Friend virus-
induced erythroleukemia is BFU-E (7). However, Friendfor the presence of DNA in each sample since the
amount of DNA isolated from a single colony of 50 cells virus is unique because it is actually a complex of two
viruses: a replication defective spleen focus forming virusor more is too low to be quantitated.
The PCR product from each colony as well as the (SFFV) and a replication competent helper virus (F-MuLV)
(18–20). The SFFV component of the complex is respon-products from the virus-infected cell line KgV and un-
cultured and bulk cultured bone marrow cells were sible for the acute erythroleukemia induced by Friend
virus (21). SFFV env gene encodes a fusion protein whichanalyzed for the presence of integrated provirus and
b actin after electrophoresis on a 1% agarose gel in mimics erythropoietin by binding to the erythropoietin
receptor expressed on erythroid cells (22–25). OtherTris borate/EDTA buffer (4). Gels were blotted and hy-
bridized with 1 1 107 counts of both 32P-E-55(/)984 MuLVs, including the E-55(/) MuLV, are replication com-
petent viruses whose env gene products are not knownprobe (4) and murine b actin probe (14). A summary
of the results from both normal and E-55(/) MuLV- to function in a manner similar to SFFV env gp55. In
these retrovirus systems, although the bone marrow hasinfected BALB.K mice analyzed in the bone marrow
colony assay is shown in Table 1. As expected, in been implicated as the site of early infection, the target
cells associated with disease have not been defined fur-all cases when bone marrow cells were isolated from
normal, uninfected BALB.K mice none of the colonies ther (2–4, 9). To identify the cell population in the bone
marrow associated with disease development in E-55(/)analyzed were positive for provirus under any culture
condition. Colony analysis of bone marrow cells incu- MuLV-induced leukemia, a series of bone marrow colony
assays was performed using IL-3, GM-CSF, and EPO.bated with various growth factors from virus-infected
BALB.K mice demonstrated that 20 – 40% of the colo- The results from the colony assays demonstrated that
with each growth factor, 20–40% of the progenitors ofnies had integrated virus. Since each colony arose
from a single progenitor cell, it appears that 20 – 40% the bone marrow from E-55(/) MuLV-infected BALB.K
mice contained integrated provirus, suggesting that tar-of the progenitor cells in the bone marrow of BALB.K
mice 1 week after injection of E-55(/) MuLV are in- get cells for the virus were either pluripotent progenitor
cells or early progenitors of multiple lineages.fected with virus. Furthermore, since virus-positive col-
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